Sanofi plans 670 job cuts in France by end 2020

PARIS: French drugmaker Sanofi told unions on Wednesday it was planning to cut 670 jobs in France, a union representative told Reuters.

The plan, which is to be set on a voluntary basis, would affect human resources, IT, and finances among others, Thierry Bodin, with the CGT union said. In addition, 80 IT jobs are to be outsourced, he said.

“This is a terrible loss of expertise. It will have consequences in terms of efficiency,” Bodin said.

Sanofi had said in September it would continue to implement cost savings after having reached a 1.5 billion euros ($1.70 billion) cost reduction target a year ahead of expectations.

“We are blindsided as Sanofi makes significant amounts of profits. And at a time of strong social tensions in France, the government is looking the other way,” Bodin said in reference to the so-called “yellow vest” protests which led to the worst riots seen in central Paris in five decades last Saturday.

A Sanofi spokesman confirmed the company’s intention to shed 670 jobs out of a 25,000 workforce in France and said the plan was to be completed by the end of 2020.

At the same time, Sanofi will invest 700 million euros in France to upgrade its production sites, notably in the areas of vaccines manufacturing and other biologic medicines.

  • Related Posts

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    New Delhi: The Parliamentary Panel on Health and Family Welfare has recommended various significant regulatory changes in the regulation of medical devices, including decentralisation of approval for all medical devices…

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory